141 related articles for article (PubMed ID: 22348407)
1. Patient- and caregiver-reported bleeding symptoms and reasons for starting and stopping treatment with recombinant factor VIIa: analysis of the Dosing Observational Study in Haemophilia (DOSE).
Valentino LA; Walsh CE; Reding MT; Young GA; Levendoglu-Tugal O; Cooper DL
Haemophilia; 2012 Jul; 18(4):554-60. PubMed ID: 22348407
[TBL] [Abstract][Full Text] [Related]
2. Patient/caregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE).
Young G; Shapiro AD; Walsh CE; Gruppo RA; Gut RZ; Cooper DL
Haemophilia; 2012 May; 18(3):392-9. PubMed ID: 22171621
[TBL] [Abstract][Full Text] [Related]
3. Assessment of individual dose utilization vs. physician prescribing recommendations for recombinant activated factor VII (rFVIIa) in paediatric and adult patients with congenital haemophilia and alloantibody inhibitors (CHwI): the Dosing Observational Study in Hemophilia (DOSE).
Gruppo RA; Kessler CM; Neufeld EJ; Cooper DL
Haemophilia; 2013 Jul; 19(4):524-32. PubMed ID: 23551918
[TBL] [Abstract][Full Text] [Related]
4. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E
Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
[TBL] [Abstract][Full Text] [Related]
5. Dosing and effectiveness of recombinant activated factor VII (rFVIIA) in congenital haemophilia with inhibitors by bleed type and location: the experience of the Haemophilia and Thrombosis Research Society (HTRS) Registry (2004-2008).
Young G; Cooper DL; Gut RZ;
Haemophilia; 2012 Nov; 18(6):990-6. PubMed ID: 22631073
[TBL] [Abstract][Full Text] [Related]
6. Exposure and safety of higher doses of recombinant factor VIIa ≥250 μg kg(-1) in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research Society Registry experience (2004-2008).
Neufeld EJ; Kessler CM; Gill JC; Wilke CT; Cooper DL;
Haemophilia; 2011 Jul; 17(4):650-6. PubMed ID: 21299750
[TBL] [Abstract][Full Text] [Related]
7. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study.
Hay CR; Negrier C; Ludlam CA
Thromb Haemost; 1997 Dec; 78(6):1463-7. PubMed ID: 9423795
[TBL] [Abstract][Full Text] [Related]
8. How we use recombinant activated Factor VII in patients with haemophilia A or B complicated by inhibitors. Working group of hematology experts from Australia and New Zealand, Melbourne, April 2011.
Brown SA; Barnes C; Curtin J; Dunkley S; Ockelford P; Phillips J; Rowell J; Smith M; Tran H;
Intern Med J; 2012 Nov; 42(11):1243-50. PubMed ID: 23157518
[TBL] [Abstract][Full Text] [Related]
9. Treatment of acute bleeds with recombinant activated factor VII during immune tolerance therapy.
Petrini P; Klementz G
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S143-6. PubMed ID: 9819046
[TBL] [Abstract][Full Text] [Related]
10. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.
Parameswaran R; Shapiro AD; Gill JC; Kessler CM;
Haemophilia; 2005 Mar; 11(2):100-6. PubMed ID: 15810910
[TBL] [Abstract][Full Text] [Related]
11. Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders.
Birschmann I; Klamroth R; Eichler H; Schenk J; Kirchmaier CM; Halimeh S
Haemophilia; 2013 Sep; 19(5):679-85. PubMed ID: 23647644
[TBL] [Abstract][Full Text] [Related]
12. Cost and effectiveness of treatments for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Korea.
You CW; Lee SY; Park SK
Haemophilia; 2009 Jan; 15(1):217-26. PubMed ID: 18754800
[TBL] [Abstract][Full Text] [Related]
13. The potential correlation between patient-reported symptoms and the use of additional haemostatic medication for joint bleeding in haemophilia patients with inhibitors: a post hoc exploratory analysis of recombinant activated factor VII data from the ADEPT2 trial.
Lentz SR; Rangarajan S; Karim FA; Andersen PD; Arkhammar P; Rosu G; Mahlangu J
Blood Coagul Fibrinolysis; 2017 Apr; 28(3):224-229. PubMed ID: 27427786
[TBL] [Abstract][Full Text] [Related]
14. Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg⁻¹) rFVIIa doses across clinical trials and registries.
Shapiro AD; Neufeld EJ; Blanchette V; Salaj P; Gut RZ; Cooper DL
Haemophilia; 2014 Jan; 20(1):e23-31. PubMed ID: 24354484
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain.
Jimenez-Yuste V; Núñez R; Romero JA; Montoro B; Espinós B
Haemophilia; 2013 Nov; 19(6):841-6. PubMed ID: 23758100
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of rFVIIa high initial dose compared to rFVIIa standard initial dose in patients with haemophilia with inhibitors using the Czech HemoRec registry.
Salaj P; Kubes R; Cetkovsky P; Capova I; Penka M; Ovesná P; Mesterton J; Lindgren P
Thromb Res; 2014 Feb; 133(2):162-7. PubMed ID: 24321420
[TBL] [Abstract][Full Text] [Related]
17. On-demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VII.
Sørensen B; Dargaud Y; Kenet G; Lusher J; Mumford A; Pipe S; Tiede A
Haemophilia; 2012 Mar; 18(2):255-62. PubMed ID: 21771206
[TBL] [Abstract][Full Text] [Related]
18. Single-dose (270 microg kg(-1)) recombinant activated factor VII for the treatment and prevention of bleeds in haemophilia A patients with inhibitors: experience from seven European haemophilia centres.
Pan-Petesch B; Laguna P; Mital A; Stanley J; Torchet MF; Salek SZ; Salaj P
Haemophilia; 2009 May; 15(3):760-5. PubMed ID: 19298382
[TBL] [Abstract][Full Text] [Related]
19. Recombinant activated factor VII safety and efficacy in the treatment of cranial haemorrhage in patients with congenital haemophilia with inhibitors: an analysis of the Hemophilia and Thrombosis Research Society Registry (2004-2008).
Nakar C; Cooper DL; DiMichele D
Haemophilia; 2010 Jul; 16(4):625-31. PubMed ID: 20158526
[TBL] [Abstract][Full Text] [Related]
20. Real-world outcomes with recombinant factor VIIa treatment of acute bleeds in haemophilia patients with inhibitors: results from the international ONE registry.
Chambost H; Santagostino E; Laffan M; Kavakli K;
Haemophilia; 2013 Jul; 19(4):571-7. PubMed ID: 23557542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
